Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: Modifications in three consecutive large surveys between 2004 and 2009

Cacoub, Patrice; Halfon, Philippe; Rosenthal, Éric; Bailly, François; Sadr, F Bani; Benhamou, Yves; Chevaliez, Stéphane; Pawlotsky, Jean‐Michel; Piroth, Lionel; Yazdanpanah, Yazdan; Pol, Stanislas

doi:10.1016/j.jhep.2010.03.009

Cited by 11 publications

(13 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An earlier diagnosis of HCV infection in HIV patients should be considered as there were more frequently asymptomatic patients among co‐infected than mono‐infected patients. The SVR rate in co‐infected patients is concordant with previously published data . Ribavirin was prescribed in 97.2% of co‐infected patients and is known to play a critical role in achieving a SVR .…”

Section: Discussionsupporting

confidence: 89%

Care of hepatitis C virus infection in France: modifications in three consecutive surveys between 1995 and 2010

Géri

Maynard

Eric

et al. 2013

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

Care of hepatitis C virus infection in France: modifications in three consecutive surveys between 1995 and 2010

Géri

Maynard

Eric

et al. 2013

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

“…The methodology used for each of these cohorts or cross‐sectional surveys has been previously detailed and published elsewhere . Data sources will be briefly described.…”

Section: Methodsmentioning

confidence: 99%

Burden of HIV and hepatitis C co‐infection: the changing epidemiology of hepatitis C in HIV‐infected patients in France

Cacoub

Dabis

Costagliola

et al. 2014

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

“…Barriers to HCV treatment are more frequent in HIV/HCV‐coinfected patients than in patients with isolated HCV infection, and mainly involve severe psychiatric disorders and ongoing alcohol use . We found that cardiovascular disease and respiratory distress were also barriers to HCV treatment initiation.…”

Section: Discussionmentioning

confidence: 81%

Factors associated with guideline‐based hepatitis C virus (HCV) treatment initiation in HIV/HCV‐coinfected patients: role of comorbidities and physicians' perceptions

et al. 2013

View full text Add to dashboard Cite

ObjectivesMany HIV-infected patients with chronic hepatitis C virus (HCV) infection do not receive treatment for HCV infection, often because of contraindications or poor adherence to anti-HIV therapy. The aim of this study was to identify factors influencing guideline-based HCV treatment initiation in a large cohort of HIV/HCV-coinfected patients. MethodsBetween 2005 and 2011, 194 (40.5%) of 479 coinfected patients not previously treated for HCV infection started this treatment based on current recommendations, i.e. a Metavir score > F1 for liver fibrosis; HCV genotype 2 or 3 infection; or HCV genotype 1 or 4 infection and low HCV viral load (< 800 000 IU/mL), whatever the fibrosis score. Clinical and biological data were compared between patients who started HCV therapy during follow-up and those who did not. ResultsIn multivariate analyses, good adherence to treatment for HIV infection, as judged by the patient's physician, was associated with HCV treatment initiation [odds ratio (OR) 2.37; 95% confidence interval (CI) 1.17-4.81; P = 0.017], whereas patients with children (OR 0.53; 95% CI 0.30-0.91; P = 0.022) and those with cardiovascular disease or respiratory distress (OR 0.10; 95% CI 0.01-0.78; P = 0.03) were less likely to be treated. ConclusionsAdherence to treatment for HIV infection, as judged by the patient's physician, appears to have a major influence on the decision to begin treatment for HCV infection in coinfected patients. This calls for specific therapeutic education and adherence support in order to ensure timely anti-HCV therapy in this population. IntroductionCompared with isolated hepatitis C virus (HCV) infection, concurrent infection by HIV and HCV results in more rapid progression towards cirrhosis and liver failure [1,2]. In the last decade, chronic liver disease, mainly resulting from HCV infection, has become one of the leading causes of morbidity and mortality in HIV-infected patients [3]. In the first published trials of anti-HCV therapy in this setting, the pegylated interferon alpha (peg-interferon) and ribavirin combination was less effective in HIV-coinfected patients. Sustained virological response (SVR) rates ranged from 14 to 38% among patients with HCV genotype 1 infection and The outcome variable was the initiation of HCV treatment, defined as the first prescription of peg-interferon and ribavirin to an HCV-treatment-naïve patient during follow-up (between 2005 and 2011). In a first analysis, clinical and biological data were compared between patients with an indication for HCV therapy and who started treatment during follow-up (patients with Ն F2 fibrosis, patients infected with genotype 2 or 3, and patients infected with genotype 1 or 4 who had a low viral load (< 800 000 IU/mL), whatever the fibrosis score), and patients who remained HCV-treatment-naïve. The second analysis was restricted to patients with a formal indication for HCV therapy, i.e. a fibrosis score Ն F2 regardless of the HCV genotype.Liver fibrosis was assessed by liver histology or noninvasive methods ...

show abstract

Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: Modifications in three consecutive large surveys between 2004 and 2009

Cited by 11 publications

References 62 publications

Care of hepatitis C virus infection in France: modifications in three consecutive surveys between 1995 and 2010

Care of hepatitis C virus infection in France: modifications in three consecutive surveys between 1995 and 2010

Burden of HIV and hepatitis C co‐infection: the changing epidemiology of hepatitis C in HIV‐infected patients in France

Factors associated with guideline‐based hepatitis C virus (HCV) treatment initiation in HIV/HCV‐coinfected patients: role of comorbidities and physicians' perceptions

Contact Info

Product

Resources

About